Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

25.12 +0.11 (+0.44%)
Streaming Delayed Price Updated: 11:49 AM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Arcus Biosciences (NYSE:RCUS) Flashes a High-Quality Technical Breakout Setup ↗
Via Chartmill
News headline image
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript ↗
CEO Rosen targets casdatifan as $5B to $10B drug with no frontline competition. 
Via The Motley Fool
Topics Earnings
News headline image
Arcus Biosciences Q2 Earnings Call Highlights ↗
Arcus Biosciences (NYSE:RCUS) outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter... 
Via MarketBeat
Topics Earnings
Arcus Biosciences (NYSE:RCUS) Beats Q2 Estimates and Advances Casdatifan Pipeline ↗
Via Chartmill
News headline image
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run ↗
This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge. 
Via The Motley Fool
Topics Regulatory Compliance
Arcus Biosciences (NYSE:RCUS) Q1 Loss Narrows But Revenues Miss Estimates; Focus Shifts to Kidney Cancer Drug Casdatifan ↗
Via Chartmill
Arcus Biosciences Inc (NYSE:RCUS) Reports Mixed Q4 2025 Results as Pipeline Strategy Pivots to Casdatifan ↗
Via Chartmill
News headline image
Arcus (RCUS) Q1 2026 Earnings Call Transcript ↗
Arcus (RCUS) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return ↗
Arcus Biosciences, a clinical-stage oncology innovator, reported significant insider selling as its stock capped a strong one-year return. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Analyst Expectations For Arcus Biosciences's Future ↗
 
Via Benzinga
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗
Via Stocktwits
News headline image
Why Did Arcus Biosciences Stock Slump 10% Today? ↗
Arcus will stop testing a domvanalimab-based drug combination in upper gastrointestinal cancers after independent reviewers found the treatment did not improve survival. 
Via Stocktwits
News headline image
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan ↗
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗
Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy. 
Via Benzinga
News headline image
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug. 
Via Investor's Business Daily
News headline image
Why Is Arcus Biosciences Stock Trading Higher On Monday? ↗
Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached. 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Arcus Biosciences's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus ↗
On CNBC's Mad Money Lightning Round, Jim Cramer endorsed buying Uranium Energy and called Arcus Biosciences a speculative play. 
Via Benzinga
News headline image
Gilead Lifts Annual Outlook As Yeztugo Launch Nears ↗
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales. 
Via Benzinga
News headline image
Arcus (RCUS) Q2 Revenue Jumps 310% ↗
Via The Motley Fool
News headline image
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences ↗
 
Via Benzinga
News headline image
Arcus Biosciences Shares Are Down Today: What's Going On? ↗
Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.